Myeloma Paper of the Day, October 15th, suggested by Robert Orlowski
Robert Orlowski shared a post on X:
“Myeloma Paper of the Day: Adapted version of the simplified frailty index may be predictive of increased NRM and inferior OS in older adults classified as frail undergoing autoHCT, allowing patient selection to keep 100-day NRM at <2%.”
Authors: Stephanie Yohay, Temitope Oloyede, Soyoung Kim, Xi Fang, Binod Dhakal, Ayesha Aijaz, Meera Mohan, Ravi Narra, Marcelo Pasquini, Anita D’Souza, Mehdi Hamadani, Ciara Louise Freeman, Othman Salim Akhtar.
Other posts featuring Robert Orlowski on OncoDaily.
Robert Orlowski, M.D., Ph.D., holds multiple positions at The University of Texas, MD Anderson Cancer Center including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine.Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.
Dr. Orlowski’s expertise lies in both clinical practice and scientific research, with a particular focus on translating laboratory discoveries into effective treatments for patients. He investigates drug resistance mechanisms in myeloma and seeks to identify predictive biomarkers for treatment response.Notably, his past contributions include leadership roles in developing proteasome inhibitors like bortezomib and carfilzomib, as well as monoclonal antibodies such as daratumumab and elotuzumab.
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023